{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-007784","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.861267+00:00","generated_at":"2026-06-05T14:51:28.715747+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lixte signs exclusive patent license with NINDS and NCI for LB-100 combination therapy","bullets":["Exclusive license covers NIH IP co-developed under CRADA; field includes checkpoint inhibitors, immunotherapy, radiation.","Upfront license issue royalty $50,000; annual minimum $30,000; earned royalties 2% on net sales (floor 1%).","Benchmark payments up to $1,225,000 tied to milestones; first Phase 2 patient dosing due October 2024.","LB-100 is first-in-class PP2A inhibitor; ongoing Phase 1b/2 OCCC trial with dostarlimab and Phase 1b SCLC trial with atezolizumab.","CEO called the collaboration a significant milestone to advance LB-100 as potentiator of cancer immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-007784","json":"https://secwatch.observer/filing/0001493152-24-007784.json","markdown":"https://secwatch.observer/filing/0001493152-24-007784.md","text":"https://secwatch.observer/filing/0001493152-24-007784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/0001493152-24-007784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T14:51:28.715747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5aa190283d4d331f993eb039a3818234571c758b","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into License Agreement with National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH) valued at $50,000 (effective 2024-02-23).","evidence_excerpt":"On February 23, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) entered into a Patent License Agreement (the “License Agreement”) with the National Institute of Neurological Disorders and Stroke (“NINDS”) and the National Cancer Institute (“NCI”), each an institute or center of the National Institute of Health (“NIH”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224007784/0001493152-24-007784-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH)"},{"label":"Value","value":"$50,000"},{"label":"Effective","value":"2024-02-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}